What is Amgen's otezla — impairment charge?

Amgen (AMGN) reported otezla — impairment charge of $800.00M in Q1 2025.

What does otezla — impairment charge mean?

A financial write-down taken when a product's expected future value drops below its current accounting value.

StatementSegment

CategoryRisk

SignalLower is better

VolatilityVolatile

First reportedQ1 2025

Last reportedQ1 2025

An increase is a negative signal indicating that the asset is underperforming or facing significant market headwinds.

This represents a non-cash expense recognized when the carrying amount of an intangible asset, such as a drug's patent o...

Comparable to asset impairment charges reported by peers when product performance fails to meet original acquisition projections.

Metric ID: amgn_segment_otezla_impairment_charge

1 periods

	Q1 '25
Value	$800.00M

What is Amgen's otezla — impairment charge?: Amgen (AMGN) reported otezla — impairment charge of $800.00M in Q1 2025.
What does otezla — impairment charge mean?: A financial write-down taken when a product's expected future value drops below its current accounting value.